aceRNA Technologies develops patient-centric genetic therapies using patented RNA switch technology to create targeted treatments that selectively affect disease-causing cells. This approach aims to provide effective cures for untreatable diseases while minimizing the burden on patients.

ACT Genomics provides genomic profiling services that deliver actionable insights on biomarkers and genomic alterations to tailor cancer treatment plans for patients. By utilizing precision testing, the company enhances treatment selection and clinical trial matching, improving patient outcomes in oncology.

The startup operates a laboratory focused on the functionality of microalgae as food ingredients, utilizing a diverse strain library and advanced screening and cultivation technologies to create a unique algae bio-foundry platform.

The startup is developing a novel analgesic drug that targets specific pain pathways to provide effective relief for patients experiencing chronic pain. By collaborating with academic institutions and healthcare professionals, the company aims to enhance patient outcomes and improve quality of life for those suffering from pain.

Arktus Therapeutics utilizes 3D printing technology to create iPS cell-derived cartilage implants for knee regeneration, addressing the widespread issue of knee pain and mobility limitations. This personalized regenerative medicine approach aims to enhance healthspan and athletic longevity by restoring natural joint function.

BiPSEE develops next-generation mental healthcare solutions by integrating Virtual Reality (VR) and Artificial Intelligence (AI) technologies. This platform aims to provide novel forms of psychological care and medical treatment delivery. The company focuses on leveraging these advanced technologies to enhance accessibility and efficacy in mental health services.

Chordia Therapeutics is focused on developing targeted therapies in oncology to improve treatment outcomes for cancer patients. The company aims to address the limitations of current cancer treatments by utilizing precision medicine approaches to tailor therapies based on individual tumor profiles.

EneCoat Technologies develops perovskite solar cells that maintain high energy conversion efficiency even in low-light conditions, utilizing a flexible film substrate for lightweight and versatile applications. The company aims to provide reliable power generation solutions for various environments, addressing the limitations of traditional solar technologies.

FIMECS develops protein degradation therapeutics using its proprietary RaPPIDS™ technology to target previously undruggable proteins associated with cancers and difficult-to-treat diseases. The company aims to provide life-saving medicines by addressing unmet medical needs through collaborations with various research institutions and industry partners.

The startup specializes in agri-bio research and development, focusing on creating new crop varieties through advanced grafting and genome editing technologies. This approach enables agricultural companies to enhance crop productivity and improve cultivation techniques, addressing the need for more efficient and resilient seedlings.

HOLOBIO develops functional gut bacteria to enhance aquaculture by improving fish health, growth, and disease resistance. Their proprietary breeding technique modifies the gut microbiome of juvenile fish, leading to more sustainable and efficient protein production.

JiMED develops a wireless brain-computer interface (BCI) that enables ALS patients to control external devices using high-resolution brainwave signals interpreted by artificial intelligence. This technology addresses the communication challenges faced by patients with severe motor impairments, providing them with a means to connect with their environment and society.

The startup develops organic semiconductor laser technology that utilizes organic fluorescent materials to create low-cost laser diodes. This technology enables the production of efficient light sources that can be seamlessly integrated into OLED and organic electronic applications, addressing the need for affordable and environmentally friendly lighting solutions.

The startup develops therapeutic drugs targeting chronic degenerative diseases, specifically for diagnosing conditions like central retinal artery occlusion and retinitis pigmentosa. These drugs enable healthcare providers to effectively manage and treat patients suffering from intractable eye diseases.

Kyoto Fusioneering supplies high‑performance gyrotron plasma heating systems, fusion fuel‑cycle modules, and blanket‑thermal‑cycle components that bridge the gap between fusion research and commercial power plants. Their turnkey "UNITY" projects integrate these subsystems, enabling energy developers and utilities to accelerate the deployment of clean, net‑zero fusion energy.

This startup offers AI-powered text analysis to forecast future trends and outcomes. Their system helps clients make informed decisions by automatically recognizing and interpreting relevant information within textual data.

Kyulux provides Hyperfluorescence™ OLED emitter materials that combine TADF sensitizers with fluorescent emitters to achieve near‑100 % internal quantum efficiency, narrow spectra and up to 60 % higher brightness than conventional phosphorescent systems. The metal‑free, cost‑effective formulation is compatible with existing OLED manufacturing processes, enabling higher‑efficiency, longer‑lifetime displays and lighting for consumer, automotive and AR/VR applications.

The startup develops targeted therapeutic methods that focus on pathogenic auto-antibodies, conducting research to understand the pathology of diseases linked to these antibodies. By creating specific treatments, the company aims to enhance patient health outcomes in conditions driven by auto-antibody activity.

Luxonus develops a non-invasive 3D imaging device utilizing photoacoustic imaging (PAI) technology, which combines pulsed light and ultrasound to generate high-resolution images without radiation exposure. This device enables detailed visualization of vascular and lymphatic structures, facilitating accurate preoperative assessments and treatment evaluations for various medical conditions.

The startup has developed a non-contact device utilizing milliwave radar technology and low-frequency irradiation to detect sleep apnea and hypopnea. This technology enables patients to achieve uninterrupted sleep by addressing the physiological factors that contribute to sleep disorders.

The startup offers a candidate verification platform that utilizes personality assessments to align job seekers' traits with corporate culture by comparing results from both applicants and current employees. This approach enhances job matching and employee retention by ensuring compatibility in values and work preferences.

Myoridge specializes in the development of high-purity myocardial cells with optimized culture media, enhancing drug response rates for cardiac research and therapies. The company addresses the challenge of inefficient cell culture processes in regenerative medicine by providing tailored media solutions and comprehensive support for cell-based product development.

The startup develops neural stem cell technologies for regenerative medicine aimed at treating central nervous system diseases, including spinal cord injuries and multiple sclerosis. By utilizing human neural stem cells as a cell therapy, the company provides targeted treatment options for conditions like Pelizaeus-Merzbacher disease.

OOYOO develops gas separation membranes specifically designed for the efficient capture of carbon dioxide and hydrogen from industrial emissions. This technology addresses the need for effective carbon capture solutions to support the transition to a carbon-neutral society.